10-Q quarterly report · filed Nov 5, 2026

Aldeyra Therapeutics, Inc. (ALDX) Q3 2026 10-Q Quarterly Report

Short answer

Aldeyra Therapeutics, Inc. (ALDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$4M
+51.1% YoY · +31.0% QoQ
EPS (diluted)
−$0.06
+53.8% YoY · +33.3% QoQ

Source: XBRL data from the Aldeyra Therapeutics, Inc. (ALDX) Q3 2026 10-Q on SEC EDGAR. USD.

Aldeyra Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue: $0, with no approved products and no product sales revenue
  • Net loss $3.8M vs $7.7M YoY, loss from operations $4.1M vs $8.0M
  • Reproxalap: primary late-stage R&D focus, approximately 30% of quarterly R&D expenses
  • Cash $41.0M at September 30, 2026, operating cash use $13.8M year-to-date
  • FDA Complete Response Letter and FDRR pending, ADX-2191 retinitis pigmentosa program suspended, AbbVie option unexercised

Risk Factors

  • Regulatory risk: 2026 Complete Response Letter triggered FDRR submission on October 26, 2026, with uncertain timing and approval outcome
  • Operational risk: Third-party reproxalap manufacturer received Form 483 deficiencies in August 2025, later classified VAI
  • Competitive risk: Dry-eye market includes Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye, and Tryptyr
  • Financial risk: Nine-month 2026 net loss $12.7 million, accumulated deficit $496.6 million, requiring substantial additional financing
  • Legal risk: FDA “radical transparency” policy creates potential Securities Class Action and SEC scrutiny following public Complete Response Letters

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Aldeyra Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.